WHO tests cross‑species Ebola vaccine amid systemic gaps in African health infrastructure and research equity
Original framing: “Can a vaccine built for one Ebola virus stop another? The World Health Organization is about to find out” — The Conversation - Global
The rVSV‑ZEBOV vaccine demonstrated 97% efficacy against the Zaire strain, but its immunogenicity against the Sudan strain remains unproven, prompting the current trial. Rigorous phase‑III data, including correlates of protection and durability of immunity, are still pending. Scientific rigor must be paired with transparent data sharing and inclusive authorship to avoid perpetuating epistemic inequities.
The WHO's cross‑species Ebola vaccine trial spotlights a moment where cutting‑edge virology meets entrenched systemic inequities, from colonial research legacies to fragile health infrastructures.
Historical patterns of resource extraction and under‑investment have repeatedly seeded spillover events, while indigenous knowledge and community rituals offer untapped reservoirs of resilience that are often ignored. By weaving scientific rigor with indigenous, artistic, and cross‑cultural insights, and by institutionalising regional manufacturing, community‑led surveillance, and One Health governance, the global health community can transform reactive miracle narratives into sustainable, equitable preparedness. Actors ranging from African ministries, local healers, and regional biotech firms to donor nations and WHO must coordinate to rewrite the script from dependency to co‑creation.